Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 4/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709621 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119459 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119456 | 1.00 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL30062876 | 0.99 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119686 | 0.99 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29398457 | 0.99 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL118173 | 0.99 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL178739 | 0.99 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29400667 | 0.99 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL31437097 | 0.98 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279888-A | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-29 | — | — | CN | claimed |
| CN-112209991-A | Tripeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-12 | — | — | CN | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-112279888-B | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-09-13 | — | — | CN | disclosed |
| CN-112209991-B | Tripeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-08-12 | — | — | CN | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-114630835-A | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2022-06-14 | — | — | CN | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| CN-112279888-A | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-29 | — | — | CN | disclosed |
| CN-112209991-A | Tripeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885CASP3 795/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885CASP3 795/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MDM4 1294/4885TP53 178/4885CASP3 3268/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885CASP3 795/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885CASP3 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.